<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 27, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161304</url>
  </required_header>
  <id_info>
    <org_study_id>T-001</org_study_id>
    <nct_id>NCT00161304</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency</brief_title>
  <official_title>Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urological Sciences Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Watson Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urological Sciences Research Foundation</source>
  <brief_summary>
    <textblock>
      The T-001 study is a placebo-controlled investigation of the effects of injectable&#xD;
      testosterone replacement therapy on prostate tissues of aging men with low testosterone&#xD;
      levels. The primary objectives of the study are to measure the changes in tissue hormones and&#xD;
      other biomarkers in the prostate tissue specimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date>November 2004</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>44</enrollment>
  <condition>Men With Low Testosterone Levels</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria&#xD;
&#xD;
          1. Male aged 50-80 years of age, ambulatory, and in good general physical and mental&#xD;
             health.&#xD;
&#xD;
          2. Clinical diagnosis of hypogonadism defined as a serum testosterone level less than 300&#xD;
             ng/dl on a morning serum sample during the screening period.&#xD;
&#xD;
          3. Answering yes to question 1 or 7 or to any three questions total on the Morley index&#xD;
             at baseline.&#xD;
&#xD;
          4. PSA &lt;10 ng/ml&#xD;
&#xD;
          5. Subject is able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Failure to meet the criteria for inclusion&#xD;
&#xD;
          2. History of allergy to testosterone or any components of the delivery system.&#xD;
&#xD;
          3. Significant abnormalities on pre-study clinical examination or laboratory&#xD;
             measurements.&#xD;
&#xD;
          4. Treatment with any investigational drug during the previous month.&#xD;
&#xD;
          5. Drug or alcohol abuse or dependence.&#xD;
&#xD;
          6. Concurrent use of testosterone and or any hormonal therapy, including health food&#xD;
             supplements and herbal products, that could alter serum testosterone levels or affect&#xD;
             the prostate (e.g. gonadotropic releasing hormone agonists, testosterone antagonists,&#xD;
             anabolic steroids, DHEA, androstenedione, PC-SPES, chrysin and tribulus terrestris,).&#xD;
             Use of alpha-reductase inhibitors or prostate phytotherapy within the past 3 months.&#xD;
&#xD;
          7. Use of antidepressant medications, oral glucocorticoids, or opioids.&#xD;
&#xD;
          8. PSA &gt; 10 ng/ml and/or prostate biopsy positive for cancer at screening. Any patient in&#xD;
             whom there is a suspicion of prostate cancer must undergo appropriate testing to rule&#xD;
             out cancer prior to entry into the study.&#xD;
&#xD;
          9. IPSS score ï‚³ 20.&#xD;
&#xD;
         10. History of malignancy of any type (except basal cell carcinoma).&#xD;
&#xD;
         11. Patients with uncontrolled diabetes.&#xD;
&#xD;
         12. Patients with known or suspected bleeding disorder. Concurrent use of Coumadin and&#xD;
             other anticoagulants at the time of biopsy or if discontinuation of such therapy prior&#xD;
             to biopsy poses a risk to the patient.&#xD;
&#xD;
         13. Inability of the patient to provide written informed consent for any reason, including&#xD;
             legal incompetence, language or comprehension difficulty, and psychological,&#xD;
             psychiatric or emotional factors.&#xD;
&#xD;
         14. Inability of the patient to have transrectal ultrasonography with biopsy (for any&#xD;
             reason).&#xD;
&#xD;
         15. A history of any illness or condition that, in the opinion of the investigator, might&#xD;
             confound the results of the study or pose additional risk to the patient.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard S Marks, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urological Sciences Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urological Sciences Research Foundation</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.usrf.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 11, 2005</last_update_submitted>
  <last_update_submitted_qc>September 11, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2005</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

